– USA, MA – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the appointment of Nancy Miller-Rich to the board of directors.
“Nancy brings enterprise-wide strategic thinking and business development expertise over more than 35 years in the pharmaceutical industry, including senior roles with Merck Pharmaceuticals and Schering-Plough,” said Richard H. Douglas, Ph.D., Chairman. “Her public company experience, particularly her strong background in areas such as licensing, joint ventures, and global commercial development, is expected to enhance our stewardship as Aldeyra continues to advance toward potential product commercialization.”
Ms. Miller-Rich’s appointment expands Aldeyra’s board of directors to eight members, seven of whom are independent directors.
About Nancy Miller-Rich
Ms. Miller-Rich is Chief Executive of Miller-Rich Associates, a pharmaceutical industry consultancy she founded in 2017. Previously, she served in leadership roles at Merck & Co., Inc. and Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough Corporation in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of Intercept Pharmaceuticals, Inc. and UDG Healthcare plc, as well as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.
“I look forward to contributing to the Aldeyra board and working closely with the leadership team to guide the company’s strategic growth,” Ms. Miller-Rich said. “Aldeyra’s pipeline comprises novel, diverse and highly differentiated therapeutic approaches to treat significant unmet medical needs. It’s gratifying to help such an innovative organization continue to achieve success.”
About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra’s lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
For more information: https://www.aldeyra.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.